

1 **Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a prospective cross-**
2 **sectional nationwide study of residual samples**

3 Herzog Sereina, PhD ^{1*}, De Bie Jessie, PhD ^{2,3*}, Abrams Steven, Prof ^{3,4}, Wouters Ine, PhD ², Ekinci
4 Esra, MSc ², Patteet Lisbeth, PhD ⁵, Coppens Astrid, MSc ⁵, De Spiegeleer Sandy, MSc ⁶, Beutels
5 Philippe, Prof ¹, Van Damme Pierre, Prof ², Hens Niel, Prof ^{1,4}, Theeten Heidi, Prof ²

6 ¹ *Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine*
7 *& Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Wilrijk, Belgium.*

8 ² *Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of*
9 *Antwerp, B-2610 Wilrijk, Belgium*

10 ³ *Global Health Institute, Department of Epidemiology and Social Medicine, University of Antwerp, B-*
11 *2610 Wilrijk, Belgium.*

12 ⁴ *Data Science Institute, I-BioStat, UHasselt, B-3500 Hasselt, Belgium.*

13 ⁵ *Algemeen Medisch Laboratorium (AML), Sonic Healthcare, B-2020 Antwerp, Belgium.*

14 ⁶ *Laboratoire Luc OLIVIER, B-5380 Fernelmont, Belgium.*

15

16 * Herzog Sereina and De Bie Jessie contributed equally to this paper

17

18 Corresponding author:

19 Sereina Herzog, Centre for Health Economics Research and Modelling of Infectious Diseases
20 (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp,
21 Universiteitsplein, 1 B-2610 Wilrijk, Belgium; herzog.sereina@gmail.com

22 **Research in context**

23 **Evidence before this study**

24 From 11 March to 6 July, updates on the COVID-19 pandemic by the World Health Organisation as
25 well as bulletins from the Belgian Scientific Institute for Public Health, Sciensano, were consulted
26 daily. Press releases and research reports from all over the world were monitored. Google, PubMed,
27 *medrxiv*, *bioRxiv* were consulted for peer-reviewed articles and preprints by searching the terms
28 “seroprevalence SARS-CoV-2” and “COVID-19”. We identified an increasing number of serosurveys
29 during the course of this study, the majority of which as yet unpublished in peer-reviewed journals.
30 Only one nationwide peer-reviewed serosurvey was published on July 6, indicating a seroprevalence
31 of 5.0% in Spain in the period of 27 April – 11 May 2020 (n=61075). Other peer-reviewed studies
32 assessed seroprevalences in specific subgroups of the population (cities). More large-scale, nationwide
33 studies are needed to assess the proportion of the population that has recently been in contact with the
34 virus, which helps to understand the likelihood of asymptomatic infections or infections with mild
35 symptoms.

36 **Added value of this study**

37 This study presents nationwide seropositivity in the Belgian population using serial serological survey
38 data from five collection periods (March 30th - July 5th 2020) allowing to monitor acquisition of
39 infections over three months time. The study period covers a lock-down mitigating the start of the
40 epidemic as well as a period of release in a densely populated European country (374 persons/km²).
41 Initial weighted overall seroprevalence was higher than expected from reported cases, and increasing
42 quickly from 2.9% (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to 7.1) over 3 weeks during lockdown
43 (from 1st to 2nd collection). The associated seroincidence was estimated at 3.1% (95% CI 1.9 to 4.3).
44 The seroprevalence stabilized at 6.9% (95% CI 5.9-8.0) in the third collection period, and
45 subsequently tended to decline to 5.5% (95% CI 4.7-6.5) and 4.5% (95% CI 3.7-5.4). A decrease is
46 observed comparing the 3rd and 5th period with a seroincidence of -2.4% (95% CI -1.0 to -3.7)
47 suggesting fast waning of IgG antibodies. Also age- and sex-specific analyses were conducted.

48 **Implications of all the available evidence**

49 Seroprevalence studies around the world indicate that up to July 2020 a minor fraction of the
50 population has been exposed to SARS-CoV-2 (e.g. in Spain 5% in May). As antibody titers after mild
51 infection seem to wane rapidly, seroprevalence estimates might only indicate exposure in the previous
52 2-3 months. Nevertheless, periodic monitoring of seroprevalence is valuable to understand age and
53 location specific rapid rises in the force of infection, to control the epidemic, and to avoid a
54 deconfinement strategy leading to large future waves. The significance of detecting SARS-CoV-2
55 humoral immune responses, irrespective of cellular immune responses, is currently unknown.
56 However, if seropositivity correlates to some extent with immunity the low peak levels of
57 seropositivity observed during this study and their rapid decline suggest that mass vaccination
58 programmes are essential to build up sufficient population immunity.

59 **Abstract**

60 **Background** In the first weeks of the COVID-19 epidemic in Belgium, a repetitive national serum
61 collection was set up to monitor exposure through SARS-CoV-2 antibody detection. Main objectives
62 were to assess the evolving age-, sex and region specific seroprevalence and seroincidence under the
63 influence of a national lock-down, which started on 17th March.

64 **Methods** This prospective serial cross-sectional nationwide seroprevalence study, stratified by age,
65 sex and region, contains 3000-4000 samples in each of its five collection periods (March 30th – July 5th
66 2020). In residual sera taken outside hospitals and collected by diagnostic laboratories, IgG antibodies
67 against S1 proteins of SARS-CoV-2 were measured with a semi-quantitative commercial ELISA.
68 Seropositivity (cumulative, by age category and sex) and seroincidence over 3 to 4 week periods were
69 estimated for the Belgian population.

70 **Findings** The weighted overall seroprevalence initially increased from 2.9% (95% CI 2.3 to 3.6) to
71 6.0% (95% CI 5.1 to 7.1), implying a seroincidence of 3.1% (95% CI 1.9 to 4.3) between the 1st and
72 2nd collection period. Thereafter, seroprevalence stabilized and decreased from the 3rd to 5th period
73 from 6.9% (95% CI 5.9 to 8.0) to 4.5% (95% CI 3.7 to 5.4).

74 **Interpretation** During lockdown, a small but increasing fraction of the Belgian population showed
75 serologically detectable signs of exposure to SARS-CoV-2. The decrease observed afterwards most
76 probably reflects rapid waning of IgG antibodies.

77 **Funding** Antwerp University Fund, the Flemish Research Fund, and European Horizon 2020.

78 **Introduction**

79 The World Health Organization (WHO) announced on 11 March 2020, that the SARS-CoV2 outbreak
80 that started in December 2019 became a pandemic.¹ Clinical symptoms caused by the virus include
81 loss of taste and smell, fever, malaise, dry cough, shortness of breath, and respiratory distress.
82 Reported illnesses have ranged from very mild to severe (from progressive respiratory failure to
83 death).² In addition, increasing age, male sex, smoking, and comorbidities such as cardiovascular
84 diseases and diabetes have been identified as risk factors for developing severe illness.³ By mid July
85 2020, over 12 million confirmed cases in 216 countries were reported to be infected by SARS-CoV-2
86 causing coronavirus disease 2019 (COVID-19).⁴

87 Currently, there is no vaccine or effective cure available to protect against or treat COVID-19.
88 Therefore, unprecedented measures such as physical distancing, large-scale isolation and closure of
89 borders, schools and workplaces were considered in many countries to mitigate the spread of the
90 disease and to reduce the corresponding pressure on the respective healthcare systems.

91 In Belgium, the first confirmed case was reported on 4 February 2020, an asymptomatic person
92 repatriated from Wuhan.⁵ The first locally transmitted cases were confirmed on 2 March 2020.
93 Thereafter, the number of confirmed COVID-19 cases rapidly increased. The Belgian Scientific
94 Institute for Public Health, Sciensano, reported that as of 9 July 2020, 62210 cases were confirmed
95 (0.5% of the Belgian population; 6.6% of the tested individuals) and 9778 died. The majority of the
96 reported Belgian cases are in the age category of 80-89 years (19.0%; 11805/62210).⁶ Knowledge on
97 and quantification of the age-specific susceptibility to SARS-CoV-2, and its evolution over time,
98 related to control measures that have been taken, is tremendously important to guide policy makers
99 aiming to control the epidemic wave and potential future waves as a result of an insufficient herd
100 immunity level in the population. These needs were translated into the following research objectives:
101 (1) to constitute a national serum bank on a periodic basis (cross-sectional study design) in order to
102 estimate the seroprevalence and seroincidence in Belgium and to follow-up trends herein over time
103 and (2) to estimate the age-specific prevalence of SARS-CoV-2 antibodies in order to identify age
104 groups that have been infected versus those that are still susceptible as a function of time. The current

105 nationwide study presents background seropositivity (overall, by age category, sex) in the Belgian
106 population using serial serological survey data from five collection periods (March 30th – July 5th),
107 which covers: (a) the implementation of the lockdown during the start of the epidemic, (b) the full
108 lockdown period (13 March – 4 May 2020), and (c) the period when confinement measures eased (4
109 May onwards).

110 **Methods**

111 **Study design**

112 This prospective cross-sectional nationwide seroprevalence study is conducted in individuals aged 0-
113 101 years. In each collection period, sera were collected over one week's time. The five collection
114 periods represent different exposure periods: (1) 30 March – 5 April 2020, mainly represents exposure
115 before the lockdown; (2) 20 – 26 April 2020, represents exposure prior to and during the start of the
116 lockdown; (3) 18 – 25 May 2020, represents exposure in full lockdown; (4) 8 – 13 June 2020,
117 represents exposure during period of first relaxation of confinement measures (re-opening of shops);
118 and (5) 29 June – 4 July 2020, represents changes during further relaxations (partial school re-opening,
119 opening of restaurants). A serum bank covering all Belgian regions was constituted by collecting
120 residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged,
121 with high daily throughput covering primary care and all kinds of ambulatory specialist care outside
122 hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in
123 hospitals were excluded. Each laboratory was allocated a fixed number of samples per age group
124 (defined in 10-year age bands, the oldest age group with ≥ 90 years), per region (Wallonia, Flanders,
125 Brussels), and per collection period. The number of samples was stratified by sex within each age
126 group.

127 The study protocol was approved by the Ethics Committee of the University Hospital Antwerp-
128 University of Antwerp on March 30, 2020 (ref 20/13/158; Belgian Number B3002020000047) and
129 agreed with inclusion without informed consent, on the condition of the samples being collected
130 unlinked and anonymously (see appendix for study protocol).

131 **Sample size**

132 The sample size per periodical collection has been calculated according to: (1) previous experience
133 with various age-specific analyses of seroprevalence data in Belgium,⁷ (2) estimates of the number of
134 COVID-19 infected people in Belgium and (3) the estimated evolution of the epidemic curve. Based
135 on case numbers (hospitalized cases confirmed with COVID-19), the overall prevalence of COVID-19

136 infection at the start of the study was estimated to be about 0.4% (42797/11460000). Based on the
137 hypothesized overall prevalence, a total sample size of 4000 in the first collection round ensures the
138 estimation of the overall prevalence with a margin of error of 0.2%; the precision regarding the age-
139 specific prevalence estimates is lower due to the division of samples across the age groups. However,
140 an increase in prevalence was expected during the study period. In total, up to 16000 sera were
141 planned to be collected, distributed over five periodic collections, and for each data collection target
142 numbers per age group were adapted according to feasibility, sample availability and aiming at
143 maximizing precision and assessing the impact of a change in epidemic control policy. The actual
144 number of samples collected per period are indicated in the result section. In collection period 1
145 (n=4000), the planned 400 samples per age category was not reached for the age categories 0-20 and
146 ≥ 90 . From collection period 2 onwards (n=3000), efforts were increased to collect samples in the
147 youngest age categories and target numbers in 70+ were decreased to maximize overall precision.

148 **Sample preparation and analysis**

149 After centrifugation of blood samples, selected residual sera (minimum 0.5 mL) were kept in the
150 fridge (4-8°C) for a maximum of 14 days and finally stored at -20°C. Serology results were obtained
151 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies
152 against S1 proteins of SARS-CoV-2 in serum (ELISA). The test was performed as previously
153 described by Lassaunière *et al.*⁸ The Dutch Taskforce Serology has compared all available data using
154 the EuroImmun ELISA and determined a specificity of 99.2% and sensitivity ranging from 64.5% to
155 87.8% in pauci-symptomatic patients and patients with severe disease, respectively, using samples
156 from patients >14 days after onset of disease symptoms.⁹ Presence of detectable IgG antibodies
157 indicates prior exposure to SARS-CoV-2, an infection which may be resolved or is still resolving, and
158 possibly protection against reinfection.^{8,10}

159 **Data management**

160 Data collected for each sample include: unique sample code, sample date, age (in years), sex, and
161 postal code of the place of residence. From the second collection period onwards, for each sample it

162 was recorded whether or not a COVID-19 diagnostic (PCR) test was requested at the collecting
163 laboratories. Samples were delivered anonymously to the investigators. Triage and check for
164 duplicates was done in the collecting laboratories before anonymization.

165 Each collection period, data were checked for completeness (based on age, sex, and postal code).
166 Serological results (SARS-CoV-2 antibodies) were linked to the database based on the sample code.
167 No further data entry was required. All files were kept on a secured server at the University of
168 Antwerp, with restricted access. Data will be stored for 20 years.

169 **Statistical analysis**

170 The serostatus of an individual was considered to be positive if the measured IgG OD values were
171 ≥ 1.1 , equivocal IgG values were considered negative. Descriptive analysis included mapping of
172 sample origin as well as serostatus (crude figures) up to municipality level per collection period.

173 For all analyses, the overall seroprevalence estimate and estimates by 10-year age bands, and sex for
174 each collection period were derived by fitting generalized linear models (binomial outcome
175 distribution) to the serostatus of the weighted samples for each collection period. Weighted
176 seroprevalence estimates are stated with the asymptotic 95% CIs using the design-based standard
177 errors. The overall seroincidence estimate and estimates by 10-year age bands, and sex between
178 collection periods were derived by calculating the difference between the corresponding estimated
179 seroprevalence from generalized linear models (binomial outcome distribution) fitted to the serostatus
180 of the weighted samples including an interaction term for the collection period. Weighted
181 seroincidence estimates are displayed with corresponding 95% CIs constructed using the multivariate
182 delta method to quantify the variability thereabout.¹¹

183 We assigned for each collection period weights to the samples such that they replicate the Belgian
184 population structure according to age, sex and provinces for 2020.¹² Weights are computed by
185 comparing the sample and population frequencies, i.e. we used a complete cross frequency table for
186 sex and 10-year age bands and a marginal distribution for the provinces. Weights were trimmed to a

187 maximum value of 3 to reduce the influence of samples in under-represented strata. All analyses were
188 done with the statistical software R (version 4.0.2) using the package survey (version 4.0).¹³

189 **Role of the funding source**

190 The funders had no role in study design, data collection, data analysis, data interpretation, writing or
191 submitting of the report. The corresponding author had full access to all the data in the study and had
192 final responsibility for the decision to submit for publication.

193 **Results**

194 A total of 16532 serum samples were collected over five 1 week periods in –March 30th-July 5th to
195 measure the anti-SARS-Cov2 IgG sero-status. The regional, age, and sex distribution of these samples
196 are shown in Table 1; deviations from the population distribution were taken into account in the
197 estimation of the weighted seroprevalences. Figure 1 shows exemplary for the collection periods 1, 2,
198 and 5 that the origin of the samples was nicely distributed throughout Belgium (panel A-C) and that
199 positive samples were spread over municipalities across Belgium (panel D-F); Figure S1 (appendix)
200 shows all collection periods. The proportion of samples that had been taken to diagnose SARS-COV2
201 infection was 2-3% in 1st and 2nd collection and afterwards 10-11%.

202 At the start, the seroprevalence estimates per age category ranged between 1.4% (20-30 years) and
203 5.9% (0-10 years) in collection period 1. The weighted overall seroprevalence showed a significant
204 increase between collection period 1 and 2, i.e. from 2.9% (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to
205 7.1) over a period of 3 weeks (Figure 2, panel A) which is also shown by the overall seroincidence
206 estimate of 3.1% (95% CI 1.9 to 4.3) (Figure 2, panel D). This significant increase in seroprevalence is
207 reflected in the age categories 20-30, 80-90, and ≥ 90 as indicated by the seroincidence estimates
208 (Figure 2, panel B+E) and within each sex (Figure 2, panel C+F). Among age categories in collection
209 period 2, the seroprevalence of the oldest category (≥ 90 years) significantly differed from the
210 seroprevalences in age categories 10-20, 30-40, 60-70, and 70-80 years.

211 In comparison with period 2, the overall seroprevalence stabilized thereafter to 6.9% (95% CI 5.9-8.0),
212 5.5% (95% CI 4.7-6.5) and 4.5 (95% CI 3.7-5.4) as shown in Figure 2 (panel A), however, a
213 significant decrease is observed when comparing the 3rd and 5th period with a seroincidence of -2.4%
214 (95% CI -1.0 to -3.7). This decrease was also observed for two subgroups: age category 40-50, and
215 females. No significant differences between males and females in seroincidence or in seroprevalence
216 were identified in any of the periods.

217 **Discussion**

218 This study reports seroprevalence and seroincidence estimates of IgG antibodies against S1 proteins of
219 SARS-CoV-2 in Belgium based on 16532 residual sera periodically collected from 30 March – 4 July
220 2020. The results indicate the state of the COVID-19 epidemic in Belgium, showing that only 2.9%
221 (95% CI 2.3-3.6) of the Belgian population had detectable antibodies against SARS-CoV-2 at the start
222 of lockdown, which doubled to 6.0% (95% CI 5.1-7.1) three weeks later but stabilized thereafter to
223 6.9% (95% CI 5.9-8.0), 5.5% (95% CI 4.7-6.5) and even decreased to 4.5% (95% CI 3.7-5.4).
224 Seropositive cases were spread over the country from the beginning. These results indicate that
225 although Belgium was heavily affected by the COVID-19 pandemic¹⁴, at the end of the study period
226 only about 7 in hundred people had (recently) been in contact with the virus.

227 Because little is known about the medical history of subjects of whom residual samples are collected,
228 any potential bias is difficult to identify and control for when estimating seroprevalences. In this study,
229 the potential for selection bias was reduced by enrolling multiple large laboratories in Belgium that
230 collect samples from ambulatory patients throughout Belgium visiting their doctor (mainly general
231 practitioners) for any reason including check-up, follow-up of pathology, allergy. Samples originating
232 from hospitals were excluded from the study to avoid disproportionate selection of subjects with acute
233 and/or severe illness including COVID-19. The majority of analyzed samples originated from two
234 private routine laboratories in Flanders (AML) and Wallonia (laboratoire Luc OLIVIER), each with a
235 large geographical network. These laboratories received 8000-23000 samples weekly for a variety of
236 purposes (biochemistry, immunochemistry, hematology, etc.). For example, among the randomly
237 selected female samples in fertile age (15-45), 11.8% had been taken for pregnancy testing, which
238 does not suggest overselection of pregnant females. From the total of 11000-33000 samples that were
239 weekly received by both labs, a fraction (1/3 to 1/11) samples were randomly selected according to the
240 stratification by age category and provinces and analyzed in this study. Residual sera have previously
241 been used in serosurveillance studies in numerous countries, including Belgium⁷, and can provide
242 valuable and representative information on immunity against infectious diseases for the general
243 population.¹⁵

244 Stringent containment measures were enforced in Belgium as of 13 March 2020. These included travel
245 bans, closures of schools, shops, factories and social gatherings in an effort to contain the spread of
246 COVID-19 and decrease its burden on public health. These intervention measures slowed down the
247 number of COVID-19 patients that were hospitalized daily. In the first two weeks of the lockdown (up
248 to 25 March 2020), over 500 cases were hospitalized daily, and this growth rate halved 4 weeks later.⁶
249 By 26 April 2020, 0.1% of the Belgian population had been hospitalized for COVID-19
250 (14639/11.46x10⁶) and 0.4% of the Belgian population had tested positive for SARS-CoV-2
251 (46134/11.46x10⁶) on a total of 345047 screened patients.⁶ The estimated seroprevalence in the week
252 of 20-26 April 2020 (6.0%, 95% CI 5.1 to 7.1) indicates that far more people had generated antibodies
253 against SARS-CoV-2 and thus had been in contact with the virus than what was expected from the
254 number of COVID-19 confirmed cases reported in Belgium on 26 April 2020 (0.4%). Clearly, the
255 reported numbers of COVID-19 confirmed cases represent an underestimation and were influenced by
256 the testing policy as testing was initially focused on the most severe cases, presenting to hospitals.
257 Asymptomatic and mild cases were less likely reported and at different stages of the first epidemic
258 wave, varying proportions of symptomatic cases presented to primary care, and varying proportions of
259 these cases were tested. By end of June, the number of daily hospital admissions in Belgium dropped
260 below 20 and the number of confirmed COVID-19 cases stabilized at a lower level than the estimated
261 seroprevalence in Belgium (see Table 2). The current seroprevalence study in the general population
262 thus allows in combination with the reported confirmed COVID-19 cases, to estimate the total number
263 of recently acquired SARS-CoV-2 infections in Belgium.

264 From the above it is clear that determination of the extent of spread of SARS-CoV-2 is a challenge as
265 typically symptomatic patients are more likely to be diagnosed. In contrast, mainly asymptomatic and
266 pauci-symptomatic subjects were included in the current study suggesting an **underestimation** of the
267 cumulative incidence of SARS-CoV-2 infection in the population. Moreover, the sensitivity of the
268 serological test used depends on the time since the onset of symptoms,⁸ thereby preventing a fraction
269 of the infected subjects to test seropositive if not infected long enough or too long prior to testing. By
270 day 14 after symptom onset, IgG against SARS-CoV-2 are detectable in serum of the majority of

271 patients.² Possibly, recent SARS-CoV-2 infected subjects may have been included in the current
272 seroprevalence study of whom antibodies were not yet detectable in blood. SARS-CoV-2 infected
273 subjects with mild or no symptoms of whom it is reported that they may develop low or no antibodies
274 against SARS-CoV-2, may have been included in this study as well.¹⁶ Moreover, recently it has been
275 reported that IgG levels start to decrease within 2-3 months after infection with SARS-CoV-2¹⁷⁻¹⁹,
276 potentially explaining the observed decline in the 5th collection round. As a result, both pauci-
277 symptomatic subjects as well as subjects that suffered from a SARS-CoV-2 infection more than 2-3
278 months ago may have been falsely seronegative, and thus also cause underestimation of the incidence
279 of infection.

280 Male **sex** has been identified as a risk factor for severe COVID-19 disease. However, SARS-CoV-2
281 susceptibility is similar for males and females and thus no difference in seroprevalence is to be
282 expected based on sex.²⁰ Nevertheless, one could argue that symptomatology goes hand-in-hand with
283 the initiation and extent of a humoral response. Since probably no severe symptomatic cases were
284 included in this study, any effect of disease severity and concomitant extent in humoral response in
285 males is not detectable.

286 The uneven infection rate of SARS-CoV-2 hampers the comparison of seroprevalence between
287 countries. A meta-analysis by Levesque et al.²¹ reported a seroprevalence of 14% in Gangelt
288 (Germany, 30 March – 10 April 2020, lockdown by 22 March, 100 households). A Swiss study
289 (Geneva, 6 April – 9 May 2020, physical distancing measures by 20 March, 1339 households)
290 estimated an increasing seroprevalence, from 4.8% (95% CI 2.4-8.0, n=341) to 8.5% (5.9-11.4,
291 n=469), to 10.9% (7.9-14.4, n=577), to 6.6% (4.3-9.4, n=604), and 10.8% (8.2-13.9, n=775) in five
292 subsequent weeks.²² A weekly serological study in Sweden (country in ‘low-scale’ lockdown) showed
293 a seroprevalence of 7.3% (n=1104) in Stockholm in the week of 27 April 2020.²³ In Spain (start
294 lockdown 14 March 2020), a national seroprevalence of 5% (4.7-5.4, n=61075) was reported in the
295 period from 27 April – 11 May 2020.²⁴ Other preliminary serological surveys from EU Member States
296 and USA reported that 1.0 - 3.4% of asymptomatic adult blood donors had antibodies against SARS-
297 CoV-2 virus in the period 20 March – 12 April 2020 (i.e. first month in lockdown in reported

298 countries).²⁵ In London (UK, start lockdown 23 March 2020), adjusted seroprevalence estimates
299 increased from 1.5% (end of March), to 15.4% (18 – 24 May 2020) and remained stable at 14.9% (8 –
300 14 June 2020). In the rest of the UK, seroprevalences are more consistent with other reports, indicating
301 between 6.3% and 6.9% (8 – 14 June 2020).²⁶ These seroprevalence estimates, as well as the ones
302 obtained in the current study provide a consistent picture and increasing incidence of infections across
303 Europe in spring 2020.

304 The plateauing of seroprevalences in this study is in accordance with findings from the UK²⁶ and
305 Spain²⁴, and can be attributed to the waning of IgG antibodies against SARS-CoV-2¹⁷⁻¹⁹ in the absence
306 of large new exposure since the start of the epidemic in Belgium. It implies that seroprevalence studies
307 on SARS-CoV-2 would only be able to give information on the past 2-3 months. To which extent
308 these recovered seronegative subjects are prone to reinfection is not known yet, as it depends, among
309 others, on eventual T-cell dependent immunity induced by the virus.²⁷ On the other hand, if presence
310 of the antibodies we measured would correlate to some extent with immunity, levels of seropositivity
311 observed during this study and their rapid decline suggest that we are still far away from natural herd
312 immunity. Based on the estimated basic reproduction number (R_0 ranges from 1.4 to 3.9),²⁸ 50 – 75 %
313 of a population would need to have protective immunity (humoral or cellular) in order to achieve herd
314 immunity mitigating subsequent waves of COVID-19.²⁹ Currently, it seems likely that natural
315 exposure during this pandemic might not soon deliver the required level of herd immunity and there
316 will be a substantial need for mass vaccination programmes to save time and lives.³⁰

317 **Conclusion**

318 Serial seroprevalence monitoring indicates that in Belgium, a densely populated country in the center
319 of Western Europe, SARS-COV-2 virus was introduced all over the country from start and the
320 proportion of the population infected doubled within 3 weeks' time from 3% to 6% during the start of
321 a lockdown to mitigate the epidemic. In line with reported confirmed cases and COVID19 deaths,
322 seroprevalence plateaued and seroincidence decreased thereafter. However, by the end of the 3-month
323 study period a decay of the proportion seropositives was observed corroborating recent reports of
324 quick antibody waning after mild or asymptomatic infection.¹⁷⁻¹⁹ Serial seroprevalence monitoring is a

325 useful tool to estimate the proportion of the population recently infected with the SARS-CoV-2 virus,
326 and helps to understand the extend of pauci- or asymptomatic infections. The findings were extremely
327 valuable to calibrate the Belgian response to the epidemic's first wave and to guide policy makers to
328 control the potential future waves. The latter is still a challenge as the low reported seroprevalences
329 (2.9-6.9%) are far from required herd immunity levels. Moreover, more research is needed to confirm
330 if seropositivity correlates to protective immunity against the virus.

331 **Data sharing**

332 The authors are willing to share original data on request.

333 **Contributors**

334 SH, JDB and IW interpreted study results and drafted and revised the manuscript. SH also contributed
335 to the study design and planned and performed statistical analysis. SA contributed to the study design,
336 planned statistical analysis, interpreted study results and revised the manuscript. EE contributed to
337 drafting the manuscript. LP and AC contributed to the study design, sample analysis and interpreted
338 the study results and revised the manuscript. SDS contributed to sample analysis and revised the
339 manuscript. PB, PVD, NH and HT contributed to the study design, interpreted the study results and
340 revised the manuscript. PVD and HT also conceived the study. NH also planned the conduct of
341 statistical analysis. All authors had access to all of the data and take full responsibility for the integrity
342 of the data, the accuracy of the data analysis, and the finished article. The corresponding author attests
343 that all listed authors meet authorship criteria and that no others meeting the criteria have been
344 omitted.

345 **Declaration of interest**

346 All authors have completed the Unified Competing Interest form available at
347 www.icmje.org/coi_disclosure.pdf and declare: support to the university from research grants from
348 GSK Biologicals, Pfizer, SANOFI, Merck, Themis, Osivax, J&J and Abbott and grants from The Bill
349 & Melinda Gates Foundation, PATH, Flemish Government and European Union, outside the
350 submitted work; no financial relationships with any organizations that might have an interest in the

351 submitted work in the previous three years; no other relationships or activities that could appear to
352 have influenced the submitted work.

353 **Acknowledgments**

354 This work received funding from the European Union's Horizon 2020 research and innovation
355 program - project EpiPose (No 101003688), the European Research Council (ERC) under the
356 European Union's Horizon 2020 research and innovation program (grant agreement 682540
357 TransMID), the Flemish Research Fund (FWO 1150017N) and from The Antwerp University Fund;
358 which is a community of donors who contribute to research and education with their personal
359 commitment through a donation, gift, bequest or through academic chairs.

360 We acknowledge the Belgian laboratories that voluntarily collected sera and data for this study:
361 Algemeen Medisch Laboratorium (AML, Antwerpen), Laboratoire Luc OLIVIER (Fernelmont),
362 Declerck Klinisch Laboratorium (Ardoonie), Klinisch Labo RIGO (Genk), Labo Anacura/Nuytinck
363 (Evergem), Labo Somedi (Heist-op-den-Berg), Labo LBS (Brussels), Laboratoire Bauduin (Enghien),
364 Medisch labo Bruyland (Kortrijk), Synlab (Luik).

365 **Figure captions**

366 **Figure 1.** Map of Belgium at municipality level, collection period 1, 2, and 5; panel A-C: number of
367 samples tested in each municipality, panel D-F: presence of IgG-positive (red) versus exclusively IgG-
368 negative (green) samples in each municipality.

369 **Figure 2.** Weighted seroprevalence (A, B, C) and seroincidence (D, E, F) estimates in Belgium overall
370 (panel A+D), by 10-year age bands (panel B+E), by sex (panel C+F).

371 **References**

- 372 1 WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 51. [www.who.int/docs/default-](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf)
373 [source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf).
- 374 2 Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of
375 probable bat origin. *Nature* 2020; **579**: 270–73. <https://doi.org/10.1038/s41586-020-2012-7>.
- 376 3 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with
377 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.
378 [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
- 379 4 WHO. Coronavirus disease (COVID-19) outbreak situation.
380 www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed Jul 13, 2020).
- 381 5 FOD. Eén gerepatrieerde landgenoot testte positief op het nieuwe coronavirus. [www.info-](http://www.info-coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus)
382 [coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus](http://www.info-coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus)
383 (accessed Apr 23, 2020).
- 384 6 Sciensano. Epidemiologische situatie. [https://covid-19.sciensano.be/nl/covid-19-](https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie)
385 [epidemiologische-situatie](https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie).
- 386 7 Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, van Damme P. Universal hepatitis B
387 vaccination in Belgium: impact on serological markers 3 and 7 years after implementation.
388 *Epidemiol Infect* 2014; **142**: 251–61. <https://doi.org/10.1017/S0950268813001064>.
- 389 8 Lassaunière R, Frische A, Harboe ZB, et al. Evaluation of nine commercial SARS-CoV-2
390 immunoassays. *medRxiv* 2020. <https://doi.org/10.1101/2020.04.09.20056325>.
- 391 9 Taskforce serologie LCT. Rapportage Status validatie van ELISA en auto-analyzer antilichaam
392 testen voor diagnostiek van SARS-CoV-2; overwegingen voor gebruik. (versie 19.05.2020).
393 [www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-](http://www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-analyzers_versie19052020_final.pdf)
394 [analyzers_versie19052020_final.pdf](http://www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-analyzers_versie19052020_final.pdf).
- 395 10 EUROIMMUN A. Application of EUROIMMUN tests for COVID-19 diagnostics. [www.coronavirus-](http://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf)
396 [diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf](http://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf) (accessed
397 Apr 29, 2020).
- 398 11 Cox C. Delta Method. In: Armitage P, Colton T, eds. *Encyclopedia of Biostatistics*. Chichester, UK:
399 John Wiley & Sons, Ltd, 2005.
- 400 12 Federal Planning Bureau. Population par province et âge, au 1er janvier. www.plan.be (accessed
401 Apr 22, 2020).
- 402 13 Lumley T. survey: analysis of complex survey samples. R package version 4.0.
- 403 14 WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 80. [www.who.int/docs/default-](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_6)
404 [source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_6](http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_6).
- 405 15 Gidding H. Australia's national serosurveillance program. *NSW Public Health Bull* 2003; **14**: 90.
406 <https://doi.org/10.1071/NB03027>.
- 407 16 van der Heide V. Neutralizing antibody response in mild COVID-19. *Nat Rev Immunol* 2020; **20**:
408 352. <https://doi.org/10.1038/s41577-020-0325-2>.
- 409 17 Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-
410 CoV-2 infections. *Nat Med* 2020. <https://doi.org/10.1038/s41591-020-0965-6>.
- 411 18 Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in
412 SARS-CoV-2 infection. *medRxiv* 2020. <https://doi.org/10.1101/2020.07.09.20148429>.
- 413 19 Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in
414 Persons with Mild Covid-19. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMc2025179>.
- 415 20 Jin J-M, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and
416 Mortality. *Front Public Health* 2020; **8**. <https://doi.org/10.3389/fpubh.2020.00152>.
- 417 21 Levesque J, Maybury DW. A note on COVID-19 seroprevalence studies: a meta-analysis using
418 hierarchical modelling. *medRxiv* 2020. <https://doi.org/10.1101/2020.05.03.20089201>.

- 419 22 Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in
420 Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* 2020.
421 [https://doi.org/10.1016/S0140-6736\(20\)31304-0](https://doi.org/10.1016/S0140-6736(20)31304-0).
- 422 23 Folkhälsomyndigheten. Första resultaten från pågående undersökning av antikroppar för covid-
423 19-virus. [www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-](http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus)
424 [resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus](http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus) (accessed May 20,
425 2020).
- 426 24 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-
427 COVID): a nationwide, population-based seroepidemiological study. *The Lancet* 2020.
428 [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5).
- 429 25 ECDC. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK - ninth update.
430 [www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-](http://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf)
431 [disease-2019-ninth-update-23-april-2020.pdf](http://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf) (accessed Apr 23, 2020).
- 432 26 Public Health England. Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report.
433 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/897481/Weekly_COVID19_Surveillance_Report_w26_UPDATED.pdf)
434 [/file/897481/Weekly_COVID19_Surveillance_Report_w26_UPDATED.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/897481/Weekly_COVID19_Surveillance_Report_w26_UPDATED.pdf).
- 435 27 Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in
436 protection. *Sci Immunol* 2020; **5**. <https://doi.org/10.1126/sciimmunol.abd6160>.
- 437 28 D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction number, R₀, based on
438 the early phase of COVID-19 outbreak in Italy. *Biosafety and Health* 2020; **2**: 57–59.
439 <https://doi.org/10.1016/j.bsheal.2020.03.004>.
- 440 29 Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher
441 compared to SARS coronavirus. *J Travel Med* 2020; **27**. <https://doi.org/10.1093/jtm/taaa021>.
- 442 30 Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective
443 immunity. *Lancet* 2020; **395**: 1527–29. [https://doi.org/10.1016/S0140-6736\(20\)30985-5](https://doi.org/10.1016/S0140-6736(20)30985-5).
444


Table 1. Description of the study population, collection period 1 till 5

		Collection period 1		Collection period 2		Collection period 3		Collection period 4		Collection period 5	
		30 Mar – 5 Apr 2020		20 – 26 Apr 2020		18 – 25 May 2020		8 – 13 June 2020		29 June – 4 July 2020	
		n	%	n	%	n	%	n	%	n	%
Number of samples		3910		3397		3242		2960		3023	
Region	Wallonia	1511	38.6	1539	45.3	1292	39.9	1100	37.2	1068	35.3
	Flanders	2195	56.1	1556	45.8	1542	47.6	1526	51.6	1621	53.6
	Brussels	204	5.2	302	8.9	408	12.6	334	11.3	334	11.0
Age in years	0-10	36	0.9	85	2.5	174	5.4	124	4.2	110	3.6
	10-20	294	7.5	442	13.0	431	13.3	375	12.7	413	13.7
	20-30	436	11.2	375	11.0	414	12.8	383	12.9	394	13.0
	30-40	461	11.8	407	12.0	424	13.1	395	13.3	396	13.1
	40-50	468	12.0	406	12.0	411	12.7	394	13.3	403	13.3
	50-60	498	12.7	430	12.7	419	12.9	393	13.3	400	13.2
	60-70	507	13.0	426	12.5	417	12.9	399	13.5	403	13.3
	70-80	506	12.9	316	9.3	236	7.3	201	6.8	204	6.7
	80-90	493	12.6	315	9.3	163	5.0	166	5.6	160	5.3
	≥90	211	5.4	195	5.7	153	4.7	130	4.4	140	4.6
Sex	male	1799	46.0	1599	47.1	1587	49.0	1425	48.1	1471	48.7
	female	2111	54.0	1798	52.9	1655	52.0	1535	51.9	1552	51.3

A


Collection period 1

medRxiv preprint doi: <https://doi.org/10.1101/2020.06.08.20125179>; this version posted July 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




B

Collection period 2




C

Collection period 5




D

Collection period 1




E

Collection period 2



F

Collection period 5











Table 2. Number of confirmed COVID-19 cases versus weighted seroprevalence in Belgium during the different collection periods

	Collection period	Average daily hospitalized cases*	Confirmed COVID-19 cases*	Weighted seroprevalence (with 95% CI)	Weighted seroincidence# (with 95% CI)
1	30 Mar – 5 Apr 2020	499	19691/11.46 milj = 0.2%	2.9% (2.3 to 3.4)	-
2	20 – 26 Apr 2020	204	46134/11.46 milj = 0.4%	6.0% (5.1 to 7.1)	3.1% (1.9 to 4.3)
3	18 – 25 May 2020	27	57342/11.46 milj = 0.5%	6.9% (5.9 to 8.0)	0.9% (-0.6 to 2.3)
4	8 – 13 Jun 2020	23	59918/11.46 milj = 0.5%	5.5% (4.7 to 6.5)	-1.4% (-2.8 to 0.03)
5	29 Jun – 3 Jul 2020	13	61727/11.46 milj = 0.5%	4.5% (3.7 to 5.4)	-1.0 (-2.3 to 0.3)

*reported at last day of collection period by Sciensano⁶; #; in comparison with previous collection period